Home The Word Brain My Amedeo FAQ Privacy About   


Chinese Coaching

Already know some Chinese? Stay on track with structured, one-on-one coaching to make steady, long-term progress. By Meng Wu and BSK.


  Leukemia

  Free Subscription


22.12.2025

1 Ann Hematol
1 Biochem Biophys Res Commun
6 Blood
9 Br J Haematol
1 Cancer
1 Cancer Lett
1 Eur J Haematol
1 Exp Hematol
1 Int J Hematol
1 J Clin Oncol
10 Leuk Lymphoma
3 Leukemia
1 Oncogene
2 PLoS One


   Retrieve available abstracts of this week’s articles:
HTML format
 
 
Single Articles


    Ann Hematol

  1. CHEN XT, Li Q, Zhao YQ, Fan SJ, et al
    Safety and efficacy of venetoclax-azacitidine combined with low-dose Idarubicin and cytarabine regimens for the treatment of newly diagnosed acute myeloid leukemia patients compared to the standard chemotherapy: a propensity score-matched real-world s
    Ann Hematol. 2025 Dec 18. doi: 10.1007/s00277-025-06653.
    PubMed        


    Biochem Biophys Res Commun

  2. SINGH P, Singh VK, Verma M
    Targeting myeloid cell leukemia-1 protein to identify potential compounds for chronic myeloid leukemia treatment: Molecular docking and molecular dynamics simulation approaches.
    Biochem Biophys Res Commun. 2025;796:153115.
    PubMed         Abstract available


    Blood

  3. WILSON NK, Gottgens B
    Breaking the silence: restoring CEBPA to fight leukemia.
    Blood. 2025;146:3014-3015.
    PubMed        

  4. CORTES JE, Hughes TP, Wang J, Kim DW, et al
    Asciminib Demonstrates Superior Efficacy and Safety in Newly Diagnosed Chronic Myeloid Leukemia in the ASC4FIRST Trial.
    Blood. 2025 Dec 15:blood.2025029210. doi: 10.1182/blood.2025029210.
    PubMed         Abstract available

  5. ZHANG L, Kang H, Valerio M, Hoang DH, et al
    Pharmacological Inhibition of miR-126 Enhances Venetoclax Activity in Acute Myeloid Leukemia.
    Blood. 2025 Dec 15:blood.2025029875. doi: 10.1182/blood.2025029875.
    PubMed         Abstract available

  6. CLOOS J, Valk PJM, Thiede C, Dohner K, et al
    2025 Update on MRD in Acute Myeloid Leukemia: A Consensus Document from the ELN-DAVID MRD Working Party.
    Blood. 2025 Dec 15:blood.2025031480. doi: 10.1182/blood.2025031480.
    PubMed         Abstract available

  7. FLEMING TJ, Antoszewski M, Lambo S, Gundry MC, et al
    CEBPA repression by MECOM blocks differentiation to drive aggressive leukemias.
    Blood. 2025;146:3019-3035.
    PubMed         Abstract available

  8. DELAFOY M, Bonnet MF, Lengline E, Cieslak A, et al
    LEF1 intragenic deletion induces a dominant-negative isoform and unveils a Wnt/beta-catenin vulnerability in T-ALL.
    Blood. 2025;146:3036-3049.
    PubMed         Abstract available


    Br J Haematol

  9. XAGORARI M, Marmarinos A, Doganis D, Nikita M, et al
    NEAT1 lncRNA overexpression results in short-term progression and poor treatment outcome in childhood B-ALL.
    Br J Haematol. 2025;207:2475-2485.
    PubMed         Abstract available

  10. QUIST-PAULSEN P, Horvei L, Dalgaard J, Moksnes M, et al
    Improved outcomes in elderly patients with acute lymphoblastic leukaemia using a paediatric-based protocol-A prospective study.
    Br J Haematol. 2025;207:2434-2440.
    PubMed         Abstract available

  11. JEN WY, Tang G, Kugler E, Croden J, et al
    MECOM fusion partner and bone marrow blast percentage influence outcomes of patients with MECOM rearranged acute myeloid leukaemia.
    Br J Haematol. 2025;207:2451-2461.
    PubMed         Abstract available

  12. LILIENTHAL I, Tao S, Nilsson C, Leonard E, et al
    Addition of hydroxyurea (hydroxycarbamide) enhances the efficacy of fludarabine/cytarabine-based salvage regimens against acute myeloid leukaemia.
    Br J Haematol. 2025;207:2462-2474.
    PubMed         Abstract available

  13. BUCHBINDER N, Michel V, Dalissier A, Kleinschmidt K, et al
    Outcomes after a second allogeneic haematopoietic stem cell transplant for relapsed paediatric acute myeloid leukaemia improved over time: A study from the EBMT Paediatric Diseases Working Party.
    Br J Haematol. 2025;207:2496-2506.
    PubMed         Abstract available

  14. BARRETT N, Gruber TA, Miyamura T, Duguid A, et al
    Infant acute lymphoblastic leukaemia-Progress from worldwide clinical efforts.
    Br J Haematol. 2025;207:2246-2260.
    PubMed         Abstract available

  15. CHEN EY, Dickman PW, Di Mari F, Dahlen T, et al
    Empirical and projected economic burden of chronic myeloid leukaemia in Sweden from 2015 to 2030: A population-based study.
    Br J Haematol. 2025;207:2441-2450.
    PubMed         Abstract available

  16. NISCOLA P
    Peripheral blood profiling of azacitidine's hypomethylation: Advancing precision medicine in juvenile chronic myelomonocytic leukaemia.
    Br J Haematol. 2025;207:2661-2662.
    PubMed         Abstract available

  17. TEFFERI A, Patnaik MM
    Chronic myelomonocytic leukaemia.
    Br J Haematol. 2025;207:2280-2282.
    PubMed         Abstract available


    Cancer

  18. FAN Z, Chen QW, Huang XY, Fu Q, et al
    Real-world efficacy and adverse events of frontline nilotinib in pediatric chronic myeloid leukemia in chronic phase: A prospective multicenter study from SCCCG[PLUS]-CML 2023.
    Cancer. 2025;131:e70225.
    PubMed         Abstract available


    Cancer Lett

  19. ZHU K, Zhang H, Li G, Zong S, et al
    lncDDR suppresses drug resistance by regulating DNA damage repair through ILF2-YB1 in T-cell acute lymphoblastic leukemia.
    Cancer Lett. 2025;639:218210.
    PubMed         Abstract available


    Eur J Haematol

  20. SAKTHIVEL M, Katneni P, Nataraja RM, Pacilli M, et al
    Central Venous Access Device Complications in Children With Leukemia: A Systematic Review and Meta-Analysis.
    Eur J Haematol. 2025 Dec 15. doi: 10.1111/ejh.70080.
    PubMed         Abstract available


    Exp Hematol

  21. WANG J, Xu J
    Splenic Erythroblasts Fuels Leukemia Progression Through Metabolic Crosstalk.
    Exp Hematol. 2025 Dec 15:105351. doi: 10.1016/j.exphem.2025.105351.
    PubMed         Abstract available


    Int J Hematol

  22. SHABBIR MA, Reyal Y, Newell B, Salisbury J, et al
    Emperipolesis, not hemophagocytosis: chronic myelomonocytic leukemia with neoplasia-associated Rosai-Dorfman disease.
    Int J Hematol. 2025 Dec 18. doi: 10.1007/s12185-025-04142.
    PubMed        


    J Clin Oncol

  23. WINGARD JR, Lee JH, Li D, Al-Mansour Z, et al
    Randomized Noninferiority Trial of a Liberalized Diet Versus the Neutropenic Diet in Hematopoietic Stem-Cell Transplant Patients and Patients With Acute Leukemia.
    J Clin Oncol. 2025 Dec 17:JCO2500889. doi: 10.1200/JCO-25-00889.
    PubMed         Abstract available


    Leuk Lymphoma

  24. KENNEDY VE, Touya M, Spalding J, Young C, et al
    Real-world treatment adherence and persistence of FLT3 inhibitors as post-alloHCT maintenance therapy in patients with AML in the United States: a cohort study using administrative claims data.
    Leuk Lymphoma. 2025;66:2697-2707.
    PubMed         Abstract available

  25. SUTTON E, Shanmuganathan N, Ross D
    Clinical and biological predictors of treatment-free remission in CML.
    Leuk Lymphoma. 2025;66:2578-2587.
    PubMed         Abstract available

  26. MARTIN C, Hill K, Isoardi K
    Application of the QT nomogram to ECG monitoring of QT prolongation in arsenic trioxide for acute promyelocytic myeloid leukaemia.
    Leuk Lymphoma. 2025;66:2728-2732.
    PubMed         Abstract available

  27. LANE AA, Papayannidis C, Angelucci E, McCloskey J, et al
    Optimizing capillary leak syndrome prevention and management in patients receiving tagraxofusp for blastic plasmacytoid dendritic cell neoplasm.
    Leuk Lymphoma. 2025;66:2569-2577.
    PubMed         Abstract available

  28. JERAJ R, Duan F, Mattison RJ, Romanoff J, et al
    Early assessment of treatment response in AML using FLT PET/cT: a trial of the ECOG-ACRIN Cancer Research Group (EAI141).
    Leuk Lymphoma. 2025;66:2765-2773.
    PubMed         Abstract available

  29. ZHANG LN, Pan WW, Qu H, Li Z, et al
    Quercetin induces apoptosis and autophagy in pediatric acute lymphoblastic leukemia by regulating miR-367/KLF4/JNK signaling axis.
    Leuk Lymphoma. 2025 Dec 16:1-17. doi: 10.1080/10428194.2025.2601321.
    PubMed         Abstract available

  30. HAZAR V, Makiya M, Yalcin K, Cadiu JT, et al
    Prognostic factors and survival outcomes of first CNS relapse in childhood acute lymphoblastic leukemia: results from the ALL-IC REL 2016 study.
    Leuk Lymphoma. 2025 Dec 16:1-7. doi: 10.1080/10428194.2025.2598861.
    PubMed         Abstract available

  31. SANCHEZ JR 2ND, Liu C, Pawar V, Huang Y, et al
    NAMPT inhibition uncovers therapeutic vulnerabilities to venetoclax and chemotherapy in acute myelogenous leukemia.
    Leuk Lymphoma. 2025 Dec 16:1-11. doi: 10.1080/10428194.2025.2571199.
    PubMed         Abstract available

  32. ARNAUD I, Rodriguez-Contreras FV, Aguirre-Munoz VY, Pulido M, et al
    Vincristine dose adjustments in adult acute lymphoblastic leukemia: impact on treatment outcomes and neuropathy.
    Leuk Lymphoma. 2025 Dec 17:1-10. doi: 10.1080/10428194.2025.2604567.
    PubMed         Abstract available

  33. LIU AJ, Batterham E, Nedumannil R, Ritchie D, et al
    Reduced burden of infection with consecutive day dosing of high dose cytarabine consolidation versus conventional dosing for acute myeloid leukemia.
    Leuk Lymphoma. 2025 Dec 18:1-13. doi: 10.1080/10428194.2025.2599991.
    PubMed         Abstract available


    Leukemia

  34. HO TC, LaMere MW, Kawano H, Byun DK, et al
    Targeting IL-1/IRAK1/4 signaling in acute myeloid leukemia stem cells following treatment and relapse.
    Leukemia. 2025 Dec 19. doi: 10.1038/s41375-025-02816.
    PubMed         Abstract available

  35. ERNST P, Lohse C, Lauseker M, Geissler J, et al
    Treatment expectations and goals among patients with chronic myeloid leukemia in Germany: a patient-centered perspective.
    Leukemia. 2025 Dec 19. doi: 10.1038/s41375-025-02826.
    PubMed         Abstract available

  36. FEDENKO A, Czapinska H, Kramer A, Stolzel F, et al
    Etiology of TP53 mutated complex karyotype acute myeloid leukemia.
    Leukemia. 2025 Dec 19. doi: 10.1038/s41375-025-02835.
    PubMed         Abstract available


    Oncogene

  37. GUO W, Wang X, Cui G, Schmieder EAS, et al
    Aberrant lipid metabolism renders an aggressive behavior of T-lymphoblastic lymphoma in a MASH model.
    Oncogene. 2025 Nov 26. doi: 10.1038/s41388-025-03630.
    PubMed         Abstract available


    PLoS One

  38. ALMUTAIRI MH, Alrubie TM
    Contrasting effects of DNA demethylation on cancer-germline gene expression in breast cancer and leukemia cells.
    PLoS One. 2025;20:e0339460.
    PubMed         Abstract available


  39. Retraction: Global incidence and mortality of childhood leukemia and its relationship with the Human Development Index.
    PLoS One. 2025;20:e0339086.
    PubMed        


Thank you for your interest in scientific medicine.


AMEDEO Leukemia is free of charge.